Phil Nadeau
Stock Analyst at TD Cowen
(4.24)
# 1,457
Out of 5,060 analysts
790
Total ratings
47%
Success rate
6.5%
Average return
Main Sectors:
Stocks Rated by Phil Nadeau
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRZN Surrozen | Reiterated: Buy | n/a | $23.44 | - | 3 | Oct 12, 2026 | |
| ELVN Enliven Therapeutics | Reiterated: Buy | n/a | $37.32 | - | 19 | Oct 7, 2026 | |
| MLTX MoonLake Immunotherapeutics | Reiterated: Buy | n/a | $9.55 | - | 21 | Oct 1, 2026 | |
| CGEM Cullinan Therapeutics | Reiterated: Buy | n/a | $12.91 | - | 1 | Sep 24, 2026 | |
| CABA Cabaletta Bio | Reiterated: Buy | n/a | $1.41 | - | 16 | Sep 2, 2026 | |
| BMRN BioMarin Pharmaceutical | Reiterated: Buy | $120 | $54.68 | +119.46% | 85 | Aug 20, 2026 | |
| ANNX Annexon | Reiterated: Buy | n/a | $3.42 | - | 19 | Aug 12, 2026 | |
| IPSC Century Therapeutics | Reiterated: Buy | n/a | $1.37 | - | 5 | Aug 12, 2026 | |
| KURA Kura Oncology | Reiterated: Buy | n/a | $9.08 | - | 22 | Aug 12, 2026 | |
| NKTX Nkarta | Reiterated: Buy | n/a | $1.80 | - | 2 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $1.90 | - | 43 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2.35 | - | 28 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $9.96 | - | 21 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $130 | $86.17 | +50.86% | 37 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $12.90 | - | 22 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $525 → $550 | $499.74 | +10.06% | 87 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $200 → $220 | $135.77 | +62.04% | 57 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $215 → $225 | $232.65 | -3.29% | 55 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $6.10 | - | 13 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $11.84 | - | 6 | Apr 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $9.18 | n/a | 18 | Mar 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.0004 | n/a | 27 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $29.96 | n/a | 31 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.28 | n/a | 4 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $8.49 | n/a | 3 | Feb 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $80 → $75 | $156.19 | n/a | 44 | Feb 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $7.52 | n/a | 12 | Nov 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $1.31 | n/a | 7 | Aug 7, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $2.18 | n/a | 6 | Feb 26, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $385 | $790.74 | n/a | 40 | Feb 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $2.00 | n/a | 14 | Jan 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $2 → $16 | $0.000001 | n/a | 14 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $205 | $432.49 | n/a | 1 | Jul 26, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $1.52 | n/a | 1 | May 3, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $185 | $533.12 | n/a | 5 | Apr 28, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $17.10 | n/a | 1 | Aug 7, 2015 |
Surrozen
Oct 12, 2026
Reiterated: Buy
Price Target: n/a
Current: $23.44
Upside: -
Enliven Therapeutics
Oct 7, 2026
Reiterated: Buy
Price Target: n/a
Current: $37.32
Upside: -
MoonLake Immunotherapeutics
Oct 1, 2026
Reiterated: Buy
Price Target: n/a
Current: $9.55
Upside: -
Cullinan Therapeutics
Sep 24, 2026
Reiterated: Buy
Price Target: n/a
Current: $12.91
Upside: -
Cabaletta Bio
Sep 2, 2026
Reiterated: Buy
Price Target: n/a
Current: $1.41
Upside: -
BioMarin Pharmaceutical
Aug 20, 2026
Reiterated: Buy
Price Target: $120
Current: $54.68
Upside: +119.46%
Annexon
Aug 12, 2026
Reiterated: Buy
Price Target: n/a
Current: $3.42
Upside: -
Century Therapeutics
Aug 12, 2026
Reiterated: Buy
Price Target: n/a
Current: $1.37
Upside: -
Kura Oncology
Aug 12, 2026
Reiterated: Buy
Price Target: n/a
Current: $9.08
Upside: -
Nkarta
Aug 10, 2026
Reiterated: Buy
Price Target: n/a
Current: $1.80
Upside: -
Aug 6, 2026
Reiterated: Buy
Price Target: n/a
Current: $1.90
Upside: -
Aug 5, 2026
Reiterated: Buy
Price Target: n/a
Current: $2.35
Upside: -
Aug 5, 2026
Reiterated: Buy
Price Target: n/a
Current: $9.96
Upside: -
Aug 4, 2026
Rated: Buy
Price Target: $130
Current: $86.17
Upside: +50.86%
Aug 4, 2026
Reiterated: Buy
Price Target: n/a
Current: $12.90
Upside: -
Aug 4, 2026
Rated: Buy
Price Target: $525 → $550
Current: $499.74
Upside: +10.06%
Jul 31, 2026
Rated: Buy
Price Target: $200 → $220
Current: $135.77
Upside: +62.04%
Jul 30, 2026
Rated: Buy
Price Target: $215 → $225
Current: $232.65
Upside: -3.29%
May 11, 2026
Reiterated: Buy
Price Target: n/a
Current: $6.10
Upside: -
Apr 29, 2026
Reiterated: Buy
Price Target: n/a
Current: $11.84
Upside: -
Mar 9, 2025
Reiterated: Buy
Price Target: n/a
Current: $9.18
Upside: n/a
Nov 13, 2024
Rated: Hold
Price Target: n/a
Current: $0.0004
Upside: n/a
Oct 31, 2024
Reiterated: Buy
Price Target: n/a
Current: $29.96
Upside: n/a
Mar 22, 2024
Rated: Hold
Price Target: n/a
Current: $3.28
Upside: n/a
Feb 13, 2023
Downgraded: Hold
Price Target: n/a
Current: $8.49
Upside: n/a
Feb 4, 2021
Reiterated: Buy
Price Target: $80 → $75
Current: $156.19
Upside: n/a
Nov 9, 2020
Reiterated: Buy
Price Target: n/a
Current: $7.52
Upside: n/a
Aug 7, 2019
Reiterated: Buy
Price Target: n/a
Current: $1.31
Upside: n/a
Feb 26, 2019
Initiated Coverage: Buy
Price Target: n/a
Current: $2.18
Upside: n/a
Feb 6, 2019
Rated: Hold
Price Target: $385
Current: $790.74
Upside: n/a
Jan 17, 2019
Reiterated: Hold
Price Target: n/a
Current: $2.00
Upside: n/a
Nov 2, 2018
Reiterated: Buy
Price Target: $2 → $16
Current: $0.000001
Upside: n/a
Jul 26, 2018
Rated: Buy
Price Target: $205
Current: $432.49
Upside: n/a
May 3, 2016
Reiterated: Hold
Price Target: n/a
Current: $1.52
Upside: n/a
Apr 28, 2016
Reiterated: Buy
Price Target: $185
Current: $533.12
Upside: n/a
Aug 7, 2015
Reiterated: Hold
Price Target: n/a
Current: $17.10
Upside: n/a